Monetta Financial Services Inc. Acquires Shares of 8,500 Illumina, Inc. $ILMN

Monetta Financial Services Inc. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,500 shares of the life sciences company’s stock, valued at approximately $1,495,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ILMN. Empowered Funds LLC grew its stake in shares of Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new position in Illumina in the second quarter valued at about $621,000. CW Advisors LLC acquired a new position in Illumina in the second quarter valued at about $275,000. Marshall Wace LLP boosted its holdings in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after buying an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC boosted its holdings in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after buying an additional 1,748 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Activity

In related news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the sale, the insider directly owned 20,338 shares of the company’s stock, valued at $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. This represents a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,415,351 shares of company stock worth $255,966,311. Insiders own 2.90% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $205.00 on Thursday. The company has a fifty day moving average price of $185.90 and a two-hundred day moving average price of $151.49. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00. The stock has a market cap of $30.95 billion, a P/E ratio of 38.25, a P/E/G ratio of 2.65 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ILMN shares. Guggenheim boosted their target price on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. lifted their price objective on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Finally, Leerink Partners increased their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.